HISTOCHEMICAL DISTRIBUTION OF CA-125 AS A PROGNOSTIC INDICATOR IN PATIENTS WITH SEROUS OVARIAN-CANCER

被引:3
|
作者
BICHEL, P
JAKOBSEN, A
ORNTOFT, TF
机构
[1] AARHUS UNIV, AARHUS KOMMUNE HOSP, INST PATHOL, DEPT CLIN CHEM, DK-8000 AARHUS, DENMARK
[2] VEJLE CENT HOSP, INST PATHOL, AARHUS, DENMARK
[3] DANISH CANC SOC, DEPT EXPTL CLIN ONCOL, AARHUS, DENMARK
关键词
CA-125; HISTOCHEMICAL DISTRIBUTION; OVARY CARCINOMA; PROGNOSIS;
D O I
10.1111/j.1525-1438.1991.tb00040.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study comprises 66 patients with stage Ill and IV serous ovarian carcinoma While the percentage of CA-125 positive cells and the staining intensity showed no correlation to patient survival, the pattern of CA-125 distribution, membranous versus cytoplasmic, was significantly correlated to survival. In accordance with other observations on switching of the antigen reaction f rom membrane to cytoplasm with increasing grade of atypia or malignancy, patients with membrane positive CA-125 tumors had a significantly better prognosis than did patients with CA-125 in the cytoplasm. Furthermore, there was excellent agreement between, on the one hand, the binding pattern of CA-125 and, on the other, the ploidy of the tumor cells and the HGI histopathologic grading index, both previously shown to be of prognostic significance.
引用
下载
收藏
页码:199 / 204
页数:6
相关论文
共 50 条
  • [1] PROGNOSTIC VALUE OF CA-125 IN ADVANCED OVARIAN-CANCER
    MOGENSEN, O
    GYNECOLOGIC ONCOLOGY, 1992, 44 (03) : 207 - 212
  • [2] CA-125 IN OVARIAN-CANCER
    VANDERBURG, MEL
    LAMMES, FB
    VERWEIJ, J
    NETHERLANDS JOURNAL OF MEDICINE, 1992, 40 (1-2): : 36 - 51
  • [3] IS SERUM CA-125 AT THE TIME OF RELAPSE A PROGNOSTIC INDICATOR FOR FURTHER SURVIVAL PROGNOSIS IN PATIENTS WITH OVARIAN-CANCER
    MAKAR, AP
    KRISTENSEN, GB
    BORMER, OP
    TROPE, CG
    GYNECOLOGIC ONCOLOGY, 1993, 49 (01) : 3 - 7
  • [4] CA-125 HALFLIFE AS NEW PROGNOSTIC FACTOR IN OVARIAN-CANCER
    MEIER, W
    STIEBER, P
    FATEHMOGHADAM, A
    HEPP, H
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 937 - 938
  • [5] OVARIAN-CANCER, INFLAMMATION, AND CA-125
    MARKMAN, M
    HOSKINS, WB
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) : 1049 - 1049
  • [6] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, EJ
    HARNDENMAYOR, P
    NAYLOR, B
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (01) : 22 - 22
  • [7] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, J
    HARNDENMAYOR, P
    NAYLOR, B
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 233 - 234
  • [8] EVALUATION OF CA-125 AS A MARKER IN OVARIAN-CANCER
    DUFFY, MJ
    DAVIS, MA
    SHEEHAN, J
    FENNELLY, JJ
    CLINICAL CHEMISTRY, 1988, 34 (06) : 1293 - 1293
  • [9] CA-125 MONITORING IN THE MANAGEMENT OF OVARIAN-CANCER
    BRUZZONE, M
    ONETTO, M
    CAMPORA, E
    CHIARA, S
    OLIVA, C
    GUIDO, T
    MERLINI, L
    PARODI, S
    BENTIVOGLIO, G
    VENTRELLA, W
    PAGANUZZI, M
    CONTE, P
    ROSSO, R
    ANTICANCER RESEARCH, 1990, 10 (5A) : 1353 - 1359
  • [10] SCREENING FOR OVARIAN-CANCER BY CA-125 MEASUREMENT
    JACOBS, I
    LANCET, 1988, 1 (8590): : 889 - 889